Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).
Seong Lin Khaw, David C Huang, Simon He, John F Seymour, Dennis Carney, Kylie D Mason, Brenda Chyla, Elizabeth Litvinovich, Evelyn McKeegan, Andrew Krivoshik, Sari Enschede, Rod Humerickhouse, Andrew W Roberts
Blood | American Society of Hematology | Published : 2009
Abstract Abstract 2374 Poster Board II-351 ABT-263 is a first-in-class BH3 mimetic inhibitor of 3 pro-survival members of the BCL2 protein family (BCL2, BCLXL, BCLW). Consistent with potent activity against BCL2-overexpressing cell lines and primary CLL cells in vitro, and BCL2-overexpressing lymphoid murine tumors in vivo, ABT-263 demonstrated significant antitumor activity in pts with relapsed, refractory CLL and small lymphocytic lymphoma (SLL) in 2 phase 1/2a studies. To date, 42 pts (35 evaluable) with CLL/SLL have been treated with ABT-263 (40-440 mg/d). 51% (18/35) with a baseline lymphocytosis >5,000 have achieved '50% reduction in lymphoc..View full abstract